News

01.05.22

Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference

SALT LAKE CITY, UT, Jan 05, 2022 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian M Strem, Ph.D., President...
Healthy Eyes Checkup
12.15.21

Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors

SALT LAKE CITY, UT, Dec 15, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) announced the appointment of David Hollander, MD, MBA, to its Board of Directors....
Healthy Eyes PR
12.14.21

Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease

SALT LAKE CITY, UT, Dec 14, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The...
Kiora Pharma - Eye Treatment
11.15.21

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

SALT LAKE CITY, UT, Nov 15, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and...
Kiora Eyegate PR - Child Eye Exam
11.06.21

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

SALT LAKE CITY, UT, November 8, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade...
10.26.21

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline WALTHAM, MA, October 26, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical...
Eye Exam
09.09.21

EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, MA, September 9, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that...
09.08.21

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers -Trial remains on track with topline data expected in Q4 2021- WALTHAM,...